LONDON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- As per The Business Research Company's Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024, the vasomotor menopausal symptoms (VMS) treatment market has witnessed substantial growth, driven by a myriad of factors including increasing awareness, government initiatives, and innovative treatment options. With a projected compound annual growth rate (CAGR) of 7.6%, the market is expected to reach $17.86 billion in 2024, marking a significant milestone in its expansion. Looking ahead, the market is poised for even stronger growth, with a projected market size of $23.11 billion by 2028, at a CAGR of 6.7%. This growth trajectory reflects the rising focus on women's health and the development of novel treatment options to address menopausal symptoms effectively.
Government Initiatives Driving Market Growth
One of the key drivers of the VMS treatment market is the government's initiatives for women's health in menopause. Governments worldwide are increasingly recognizing the importance of addressing menopausal symptoms and supporting women's health during this transition phase. These initiatives encompass funding for innovative studies on menopausal transition, illness prevention, and research related to pharmacological, clinical, and epidemiological aspects. For example, the Government of New South Wales in Australia initiated a $40.3 million investment over four years to develop new programs for women facing severe menopausal symptoms. Such initiatives not only raise awareness about menopausal health but also drive the demand for advanced treatment options, thereby fueling market growth.
Learn More In-Depth On The Vasomotor Menopausal Symptoms (VMS) Treatment Market
Innovative Treatment Options
Major players in the VMS treatment market are at the forefront of developing innovative treatment options to meet the evolving needs of patients. These companies are investing in research and development to introduce new drugs and therapies that offer improved efficacy and safety compared to existing treatments. For instance, Astellas Pharma Inc. received FDA approval for Veozah (fezolinetant), the first nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for treating menopausal-related VMS. This hormone-free option provides an alternative treatment for women experiencing VMS, particularly those who cannot or prefer not to use hormone therapy. Similarly, Amyris Inc.'s acquisition of MenoLabs LLC underscores the company's commitment to expanding its presence in the women's health market and leveraging new technologies to address menopausal symptoms.
Market Landscape and Opportunities
The VMS treatment market is characterized by the presence of several major players, including Pfizer Inc., Abbvie Inc., and Novartis AG, among others. These companies are focusing on developing a diverse portfolio of products and expanding their market presence through strategic acquisitions and partnerships.
North America leads the vasomotor menopausal symptoms (VMS) treatment market, accounting for the largest share of total revenue in 2023.
The vasomotor menopausal symptoms (vms) treatment market covered in this report is segmented –
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Get A Free Sample Of The Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Report
https://www.thebusinessresearchcompany.com/sample_request?id=13051&type=smp
In conclusion, the vasomotor menopausal symptoms (VMS) treatment market is poised for strong growth in the coming years, driven by increasing awareness, government initiatives, and innovative treatment options. As governments worldwide continue to prioritize women's health and invest in research and development, the market is expected to witness significant expansion.
Major players in the vasomotor menopausal symptoms (VMS) treatment market are actively investing in research and development to introduce new drugs and therapies that offer improved efficacy and safety, thereby meeting the evolving needs of patients. With ongoing advancements and strategic initiatives, the future of the VMS treatment market looks promising, offering vast opportunities for growth and development in the years to come.
Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024 by The Business Research Company provides insights on the vasomotor menopausal symptoms (VMS) treatment market size, vasomotor menopausal symptoms (VMS) treatment market segments, vasomotor menopausal symptoms (VMS) treatment market trends, drivers and restraints, major competitors' market positioning, revenues and market shares.
The Business Research Company has published over 7,500+ industry reports, covering more than 2,500+ market segments and 60 geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Check Out Similar Market Intelligence Reports By The Business Research Company:
Postmenopausal Osteoporosis Treatment Global Market Report 2024
Menopausal Hot Flashes Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report
PMS And Menstrual Health Supplements Global Market Report 2024
Learn More About The Business Research Company
The Business Research Company is a market intelligence firm pioneering in company, market, and consumer research. With offices all around the world, TBRC has specialist consultants in a variety of fields, including manufacturing, healthcare, financial services, chemicals, and technology.
Global Market Model – World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293 Email: info@tbrc.info Follow us on: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
